Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR039 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma
NCT05149391Phase 1Completed
- Sponsor
- Peking University
- Start
- Jul 2021
- Primary completion
- Jan 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of prizloncabtagene autoleucel in B-cell non-Hodgkin lymphoma, sponsored by Peking University. Primary endpoint: Incidence and severity of adverse events up to 24 months. Started Jul 2021; status: completed.
02
Drugs
prizloncabtagene autoleucel
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05149391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05149391.